WHO warnings: COVID‑19 threatens to derail lifesaving AIDS medicines
According to a new WHO survey, over one‑third of the world’s nations now face potential shortages of essential antiretroviral (ARV) drugs that keep people living with HIV alive and healthy. The pandemic’s supply chain hiccups and restrictions on travel are the main culprits.
Key facts from the report
- Out of 73 countries examined, 24 are already struggling with critically low ARV stocks.
- These 24 nations cover about 8.3 million people—roughly a third of all those on HIV treatment worldwide.
- Current global HIV infection estimates sit at 38 million.
Why the shortages matter
While there’s no cure for HIV, ARVs are the frontline defence, controlling the virus and preventing its spread. A breakdown in drug supply could reverse decades of progress, allowing the virus to rebound unchecked.
What’s causing the disruption?
- Late or failed deliveries from suppliers.
- Massive cuts in land and air transport.
- Limited patient access to clinics and testing sites.
WHO’s response
To keep treatment going, the WHO recommends “multi‑month dispensing” of AIDS drugs—so patients can receive up to six months’ worth of medication in one go, reducing the need for frequent clinic visits.
Take‑away
In the midst of the COVID‑19 crisis, keeping ARVs flowing is essential. World leaders and health workers must step up to ensure that people with HIV aren’t left behind as the pandemic stretches resources thin.
